Skip to content
Parakho

Concord Biotech Ltd

NSE CONCORDBIOBSE 543960concordbiotech.comInvestor relations

Q1 FY27, unaudited

Revenue
₹257.49 Cr
Profit after tax
₹57.70 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations257.49+26.23%1,054.89
Other income12.83−6.23%52.36
Total income270.31+24.19%1,107.25
Employee benefit expense43.64+15.15%176.90
Finance costs0.04−37.88%0.28
Depreciation & amortisation18.10+1.82%74.46
Total expenses193.25+20.46%762.23
Profit before tax77.07+34.64%341.74
Tax expense20.65+40.70%85.42
Profit after tax57.70+30.96%259.23
Total comprehensive income74.76+81.28%314.47
Earnings per share
Earnings per share, basic₹5.52₹24.78
Earnings per share, diluted₹5.52₹24.78

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Q1 FY27

Concord Biotech reported Q1 FY27 revenue of INR257 crores, up 26.2% year-on-year, driven by export growth of 46% and broad-based gains across immunosuppressants, anti-infectives, oncology and antifungal categories. EBITDA grew 34% to INR82 crores with margins of 32%, while PAT rose 31% to INR58 crores. Management attributed the growth to new product launches, wallet share gains from pricing advantages, and spillover of delayed customer procurement from the prior year.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 40 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 21 Aug 2026.